Burcon Files NASDAQ Listing Application

Vancouver, Canada (ots/PRNewswire) -

Burcon NutraScience Corporation ("Burcon" or the "Company") is
pleased to announce that it has filed an application to list its
common shares on the NASDAQ Stock Market LLC and has filed a
registration statement to register its common shares on Form 40-F
with the United States Securities and Exchange Commission (the
"SEC"), pursuant to section 12 of the United States Securities
Exchange Act of 1934.

Listing of the Company's common shares on NASDAQ is subject to
receipt of all necessary regulatory approvals, including NASDAQ and
the SEC and is expected to take until the end of September or mid
October 2011. In connection with the filing of its Form 40-F, the
Company has filed on SEDAR its 2011 consolidated financial statements
prepared in accordance with International Financial Reporting
Standards.

"This listing is a natural evolution for our company," said Johann
F. Tergesen, president and COO of Burcon, adding "Under the
previously announced CLARISOY(R) soy license agreement, Archer
Daniels Midland Company, our US-based partner, has an exclusive and
global license for the production, distribution and sale of
CLARISOY(R) across all geographic regions and all product uses and we
expect initial commercial sales of CLARISOY(R) by ADM will be in the
United States. Having our shares traded on NASDAQ will make it easier
for investors in the United States to invest in Burcon thus
increasing our liquidity and addressing demand for our shares from
investors south of the border. This listing will not involve any
money raise or issuance of shares from treasury."

Burcon also reports that we have recently received notice from the
United States Patent and Trademark Office that two of our U.S. patent
applications have now proceeded to grant as United States patents.
The first U.S. Patent - titled "Canola Protein Isolate Functionality
II" (US Patent No. 7,989,017) covers functional applications of
blends of Burcon's canola protein isolates Puratein(R) and
Supertein(TM) in food and beverage products. The second U.S. Patent -
titled "Canola Protein Isolate" (US Patent No. 7,981,450) covers
extraction procedures that improve the quality and purity of
Supertein(TM) canola protein isolate.

"We have been encouraged by recent transactions in the general
intellectual property markets," said Johann F. Tergesen, president
and COO of Burcon, adding "Strategic buyers have been recognizing the
value inherent in a patent portfolio's ability to protect a product's
market.

We have seen increased interest from a variety of participants in
our market place in all aspects of our products and our patents.
Burcon's business strategy has been to develop a sound patent
portfolio that broadly protects our core inventions. In general we
have sought to protect our processing technologies, the functional
applications of our novel proteins as they may be used in end
products, and also to protect the signature characteristics of the
proteins themselves. To-date, our patent portfolio consists of 170
issued patents in various countries, including 29 issued U.S.
patents, and in excess of 300 additional pending patent applications,
72 of which are U.S. patent applications."

About Burcon NutraScience Burcon is a leader in nutrition, health
and wellness in the field of functional, renewable plant proteins.
Since 1999, Burcon has developed a portfolio of composition,
application, and process patents originating from our core protein
extraction and purification technology. We are developing Puratein(R)
and Supertein(TM) canola protein isolates with unique functional and
nutritional attributes, and CLARISOY(R), a revolutionary soy protein
isolate which is 100% soluble and completely transparent in low pH
solutions. Our team of highly specialized scientists and engineers
work from our private research facility to develop and optimize
environmentally sound technologies. To-date, our patent portfolio
consists of 170 issued patents in various countries, including 29
issued U.S. patents, and in excess of 300 additional pending patent
applications, 72 of which are U.S. patent applications.

ON BEHALF OF THE BOARD OF DIRECTORS "Johann F.
Tergesen" Johann F. Tergesen President and Chief
Operating Officer

The TSX has not reviewed and does not accept responsibility for
the adequacy of the content of the information contained herein. This
press release contains forward-looking statements that involve risks
and uncertainties. These forward-looking statements relate to, among
other things, plans and timing for the introduction or enhancement of
our products, statements about future market conditions, supply and
demand conditions, and other expectations, intentions and plans
contained in this press release that are not historical fact. Our
expectations regarding the prospect for future success depend upon
our ability to develop and sell products, which we do not produce
today and cannot be sold without further research and development or
reliance on our development partner. When used in this press release,
the words "goal", "intend", "believes" and "potential" and similar
expressions, generally identify forward-looking statements. These
statements reflect our current expectations. They are subject to a
number of risks and uncertainties.

For further information: Jade Cheng, Chief Financial
Officer Burcon NutraScience Corporation
+1-604-733-0896 / (888)408-7960 toll-free [email protected]
http://www.burcon.ca

Rückfragehinweis:
.

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print